Veloxis Pharmaceuticals
Veloxis has developed Envarsus® XR (once daily tacrolimus extended-release tablets) based upon the company’s delivery technology, MeltDose®.
The company markets Envarsus® in USA. This immunosuppressant is used to prevent organ rejection after transplantations. Marketing partner in Europa is Chiesi
